Biotech

All Articles

AN 2 halves head count, quits stage 3 trial after data dissatisfy

.AN2 Therapies is rethinking its own company in action to poor midphase data, vowing to lay off half...

Merck pays $700M for bispecific, spying autoimmune position and possibility to test Amgen in cancer cells

.Merck &amp Co. is paying $700 million upfront to test Amgen in a blood stream cancer cells market. ...

Gilead spends J&ampJ $320M to leave licensing deal for seladelpar

.Along With Gilead Sciences almost an FDA selection for its liver disease medicine seladelpar, the f...

' All hands on deck' at Lilly as peers target excessive weight market

.CEO David Ricks can observe the firms establishing camping tents at basecamp behind Eli Lilly in an...

Entero laying off personnel, abandoning workplace and also pausing R&ampD

.Mattress Liquidators has actually transformed Entero Therapies white as a slab. The collector got E...

Exelixis drops ADC after deciding it is actually no suit for Tivdak

.Exelixis is losing hope on its own cells element (TF)- targeting antibody-drug conjugate after wrap...

Relay loses interest in SHP2 inhibitor after Genentech leaves

.3 full weeks after Roche's Genentech device walked away from an SHP2 prevention pact, Relay Therape...

Stoke's Dravet syndrome med launched of partial clinical grip

.Stoke Rehabs' Dravet disorder medication has actually been freed from a predisposed grip, removing ...

Fierce Biotech's Gabrielle Masson provides Intense 15 at NYSE

.Tough Biotech Partner Editor Gabrielle Masson presented the 2024 course of Tough 15 champions on th...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has actually axed its own once-monthly double GLP-1/ GIP receptor agonist, ending (PDF...